We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

ERBA MANNHEIM

Erba Mannheim is an IVD solutions provider focused on improving health outcomes in developing nations. Originally fou... read more Featured Products: More products

Download Mobile App





Erba Mannheim Announces Availability of Validated Automated Protocols for ErbaLisa COVID-19 IgG and IgM ELISA Kits

By LabMedica International staff writers
Posted on 01 Sep 2020
Erba Mannheim (London, England) has announced availability of validated automated protocols for its range of ErbaLisa COVID-19 IgG and IgM ELISA kits in order to improve global availability of high-quality testing methods for SARS-CoV-2.

The ready-to-use ErbaLisa COVID-19 IgG and IgM ELISA kits allow for the qualitative and semi-quantitative detection of IgG/M antibodies to SARS-CoV-2 in human serum. More...
Erba's solid phase assays use proven technology, and total incubation time is 50 minutes at room temperature with a simple one step serum dilution. ErbaLisa COVID-19 assays are built for superior performance and reliable interpretation of results. With full CE certification, the reliable and automation-friendly COVID-19 ELISA kits are now available through Erba's global distribution network, including in the US.

Optimized protocols for popular instruments manufactured by Dynex, Stratec, Awareness, and Delta Biologicals are now available, as well as for Erba's own analyzers including the ELAN 30s microstrip processor. Such protocols will help meet or exceed manual performance characteristics and start reporting clinical results faster and with more confidence.
"With more than one million ELISA COVID-19 tests already issued, we are confident this development will help labs adopt our high quality and high value tests more quickly," said Nikhil Vazirani, MD of Erba Mannheim.



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
New
Thyroid Test
Anti-Thyroid EIA Test
New
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The integrated polygenic risk score combines information from multiple genetic variants into a single test that provides a result for each of eight cardiovascular conditions (photo credit: Adobe Stock)

Genomic Risk Score Identifies Inherited Risk for Multiple Cardiovascular Conditions

Cardiovascular disease is the leading cause of death worldwide, yet many at‑risk individuals are overlooked by traditional calculators. Tools that weigh age, sex, blood pressure, and cholesterol can miss... Read more

Pathology

view channel
Image: Study flowchart. This study developed a multimodal artificial intelligence framework to predict PIK3CA mutations in breast cancer (Jiaxian Miao et al., Cancer Biol Med 23(3): 430–450 (2026). DOI: 10.20892/j.issn.2095-3941.2025.0771)

Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment

PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.